Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells

Journal of Rheumatology

Volumn 33, Issue SUPPL. 77, 2006, Pages 3-11

  Dörner, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Clinical Hemostaseology and Rheumatology ^*  (Germany)

Author keywords

Autoantibodies; B cells; Pathogenesis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; AUTOANTIBODY; BELIMUMAB; BIOLOGICAL PRODUCT; CD20 ANTIBODY; CD20 ANTIGEN; CD22 ANTIGEN; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRATUZUMAB; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN LAMBDA CHAIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; MEMBRANE ANTIGEN;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ARTHROPATHY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CLINICAL STUDY; COMORBIDITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; JOINT DESTRUCTION; MEMORY CELL; NONHODGKIN LYMPHOMA; PLASMA CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; B LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION;

EID: 84856488806     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Panayi GS. The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics. Agents Actions Suppl 1995;47:1-21.
2. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 2004;20:517-27.
3. Horneff G, Emmrich F, Burmester GR. Advances in immunotherapy of rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies. Br J Rheumatol 1993;32 Suppl 4:39-47.
4. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
5. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004;16:246-53.
6. Golovkina TV, Shlomchik M, Hannum L, Chervonsky A. Organogenic role of B lymphocytes in mucosal immunity. Science 1999;286:1965-8.
7. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-50.
8. Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol 2003;21:205-30.
9. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005;202:321-31.
10. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171-7.
11. Hoyer BF, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004;199:1577-84.
12. Tarlinton DM, Hodgkin PD. Targeting plasma cells in autoimmune diseases. J Exp Med 2004;199:1451-4.
13. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
14. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80.
15. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996;93:221-5.
16. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
17. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
18. Dorner T, Hansen A. Autoantibodies in normals - the value of predicting rheumatoid arthritis. Arthritis Res Ther 2004;6:282-84.
19. Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003;15:246-52.
20. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97:188-96.
21. Gause A, Berek C. Role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. BioDrugs 2001;15:73-9.
22. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62 Suppl 2:ii55-ii59.
23. Zhang Z, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10
24. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13.
25. Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology Oxford 2005;44:176-82.
26. Dorner T, Lipsky PE. Immunoglobulin variable-region gene usage in systemic autoimmune diseases. Arthritis Rheum 2001;44:2715-27.
27. Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res 2000;2:126-31.
28. Korthauer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993;361:539-41.
29. Magalhaes R, Stiehl P, Morawietz L, Berek C, Krenn V. Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Arch 2002;441:415-27.
30. Hutloff A, Buchner K, Reiter K, et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004;50:3211-20.
31. Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998;102:938-46.
32. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002;46:2160-71.
33. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74.
34. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37:820-8.
35. Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005;37:829-34.
36. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003;171:5215-24.
37. Martin F, Dixit VM. Unraveling TACIt functions. Nat Genet 2005;37:793-4.
38. Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174:864-70.
39. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9.
40. Odendahl M, Keitzer R, Wahn U, et al. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 2003;62:851-8.
41. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42.
42. Goodnow CC, Sprent J, Fazekas de St GB, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005;435:590-7.
43. Lindenau S, Scholze S, Odendahl M, et al. Aberrant activation of B cells in patients with rheumatoid arthritis. Ann NY Acad Sci 2003;987:246-8.
44. Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2005;7:R1001-R1013.
45. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001;167:2361-9.
46. Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8.
47. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8.
48. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27.
49. Horneff G, Burmester GR, Emmrich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129-40.
50. Protheroe A, Edwards JC, Simmons A, Maclennan K, Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology Oxford 1999;38:1150-2.
51. Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W. Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 2001;60:892-3.
52. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
53. Cohen SB. Updates from B-cell trials: Efficacy. J Rheumatol 2006;33 Suppl 77:xx.
54. Roll P, Palanichamy A, Rouziere A, Doerner T, Kneitz C, Tony HP. B cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: transient recirculation of plasmablasts and increased levels of germinal center founder cells during the early regeneration phase. [abstract]. Arthritis Rheum 2005;52 Suppl:S289.
55. Rosen O, Hiepe F, Massenkeil G, Thiel A, Arnold R. Relapse of systemic lupus erythematosus. Lancet 2001;357:807-8.
56. Emery P, Sheeran T, Lehane PB, Saiedabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. [abstract]. Arthritis Rheum 2004;50 Suppl:S659.